Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.
about
Dendritic cell-based immunity and vaccination against hepatitis C virus infectionNovel recombinant alphaviral and adenoviral vectors for cancer immunotherapyProgress and prospects: immune responses to viral vectorsAdenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP componentBovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccinesNovel vaccines to human rabiesPrime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responsesAdenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.Protection of non-human primates against rabies with an adenovirus recombinant vaccine.Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster modelMucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectorsThe influence of delivery vectors on HIV vaccine efficacyAdenovirus-based vaccines: comparison of vectors from three species of adenoviridae.Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectorsImmune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.Cofactors that may influence vaccine responses.The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses.Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly.An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.Gene therapy for rhesus monkeys heterozygous for LDL receptor deficiency by balloon catheter hepatic delivery of helper-dependent adenoviral vector.Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines.Effect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vectorRecombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challengeImplications of the innate immune response to adenovirus and adenoviral vectors.Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and catsLong-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth diseaseCapsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primatesApplication of recombinant adenoviruses expressing glycoprotein or nucleoprotein of rabies virus to Korean raccoon dogsAdenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria VaccineLack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunityPreexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine
P2860
Q26828003-E215B507-862F-4C4A-8E01-AE9FF267F3EAQ27013586-7B69BB8D-6D22-40E8-A512-647A61933342Q28264531-D8004371-73F8-47A5-BB13-FD579FCF455EQ28744136-0DA14E88-A683-4943-BD50-9B1C3115B78DQ30229074-89E724C4-2C86-47F9-B6D1-C22EBA89E343Q30378897-CCB97B52-FB84-49FA-88C4-638E11AF7076Q30422006-3DDF42F3-0428-422E-85D6-A7E209D3E488Q33424498-19DCEBD7-E39F-4EB4-AE79-53DB90376EBDQ33507253-DA78471D-D94F-4242-954A-12809C1CE08CQ33557760-D727E3FC-2D91-4F3D-BEFE-1701BF0C77F3Q33601808-07173772-D45A-4488-B269-629FFDBA6015Q33684288-AF67D815-34FF-414E-AA34-3C44B62FFBADQ33713048-F15082DE-488D-4580-8F28-71CFD4737455Q33743800-368F6B8D-4AD1-40A9-8F4E-69C4BB64158DQ33950119-7CC81D82-9347-48E7-AC7A-4DA235367CADQ34057708-8AE6CA3D-7185-4BCC-A2F8-00CBB2B3AE5DQ34077543-5DE7D4AD-329A-479A-9BF7-B75A61E28F53Q34178208-A8679E63-A7E2-4794-AE13-7CE6E471746DQ34204440-ADA5DA78-0B5B-4E43-8AA5-E0C316441261Q34260720-AAB8CE8D-865A-4053-A07A-C3F79C2F590BQ34297930-E6BCF829-F6D1-443C-8AA8-276225CC6D76Q34341345-DDAC9202-1D49-44E4-B1DB-CC2C3C7E7B5CQ34531535-95CC6A7D-25E5-4814-9870-63129B4BADA6Q34575993-030D1C0C-B88F-4739-8B6B-38BAB070FDADQ34810377-65896BA9-4C0A-4D81-9345-ED59221F9FD4Q34892789-9EDAA3E3-4750-49AF-BC94-A8103436DF07Q34992681-76F7CE1C-311D-4AC2-A95A-DCAD0FFA9DD1Q35022798-C06A0247-6DE4-4E19-B52D-716332CCCA50Q35076828-DB359D07-2586-411A-AE22-2198F3FA16C0Q35085363-D18EB24B-039E-45A3-A9A1-0D4E2C7D03E8Q35140435-D469F400-55EE-43A3-8AE1-EEA22C195252Q35191980-41862AE4-1677-4A1D-8D74-F51FA2F17175Q35317858-7AE4AFF0-A675-4760-84A3-4B5A39F73673Q35345853-E10CACD9-8ECB-4491-BE91-4457CC8B0349Q35568563-B16B74EE-1506-4439-8A86-4613E36025F0Q35916227-E8AE01EA-DDB8-418C-891B-7F156A00B28CQ35990696-A6EEC9B2-93FD-4F0C-88C6-4034AA48C45FQ36003208-B5B5266C-FA4A-485F-BD5A-93D94E003335Q36086236-D76AA6DB-3332-4DF4-8161-E6B88880A8ADQ36141586-8A25EBD7-40C5-4511-A997-FA1FEA65A781
P2860
Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Effect of preexisting immunity ...... ee-derived adenovirus vectors.
@ast
Effect of preexisting immunity ...... ee-derived adenovirus vectors.
@en
type
label
Effect of preexisting immunity ...... ee-derived adenovirus vectors.
@ast
Effect of preexisting immunity ...... ee-derived adenovirus vectors.
@en
prefLabel
Effect of preexisting immunity ...... ee-derived adenovirus vectors.
@ast
Effect of preexisting immunity ...... ee-derived adenovirus vectors.
@en
P2093
P2860
P356
P1433
P1476
Effect of preexisting immunity ...... ee-derived adenovirus vectors.
@en
P2093
Birgit Korioth-Schmitz
Dongming Zhou
Hildegund C J Ertl
Kimberly McCoy
Marcio O Lasaro
Nia Tatsis
Norman L Letvin
Scott E Hensley
Shih-Wen Lin
P2860
P304
P356
10.1128/JVI.02497-06
P407
P577
2007-04-11T00:00:00Z